Vera Therapeutics, Inc. - Sell
Zacks' proprietary data indicates that Vera Therapeutics, Inc. is currently rated as a Zacks Rank 4 and we are expecting a below average return from the VERA shares relative to the market in the next few months. In addition, Vera Therapeutics, Inc. has a VGM Score of D (this is a weighted average of the individual Style Scores which allow you to focus on the stocks that best fit your personal trading style). Valuation metrics show that Vera Therapeutics, Inc. may be overvalued. Its Value Score of D indicates it would be a bad pick for value investors. The financial health and growth prospects of VERA, demonstrate its potential to underperform the market. It currently has a Growth Score of F. Recent price changes and earnings estimate revisions indicate this would be a good stock for momentum investors with a Momentum Score of A.
Style Scorecard
Value Scorecard
Growth Scorecard
Momentum Scorecard
Value Score | VERA: D | Industry [X] | ABOS: C | AADI: D | ABCL: F |
---|---|---|---|---|---|
Zacks Rank | 4 | 3 | 4 | 2 | |
VGM Score | D | D | F | F | |
Cash/Price | 0.20 | 0.44 | 1.49 | 2.32 | 0.79 |
EV/EBITDA | -17.13 | -1.10 | 0.97 | 0.73 | -1.36 |
PEG Ratio | NA | 2.26 | NA | NA | NA |
Price/Book (P/B) | 5.64 | 2.16 | 0.65 | 0.42 | 0.81 |
Price/Cash Flow (P/CF) | NA | 16.71 | NA | NA | NA |
P/E (F1) | NA | 24.76 | NA | NA | NA |
Price/Sales (P/S) | NA | 6.56 | NA | 1.60 | 25.64 |
Earnings Yield | -6.39% | -27.13% | -37.59% | -163.87% | -19.23% |
Debt/Equity | 0.14 | 0.00 | 0.12 | 0.00 | 0.00 |
Cash Flow ($/share) | -1.91 | -1.53 | -0.96 | -2.80 | -0.40 |
Growth Score | VERA: F | Industry [X] | ABOS: D | AADI: F | ABCL: F |
---|---|---|---|---|---|
Zacks Rank | 4 | 3 | 4 | 2 | |
VGM Score | D | D | F | F | |
Hist. EPS Growth | NA | 2.51% | NA% | NA% | NA% |
Proj. EPS Growth | -4.19% | 19.19% | 1.62% | -4.10% | -18.04% |
Curr. Cash Flow Growth | 11.32% | -2.92% | 31.06% | 25.19% | -160.28% |
Hist. Cash Flow Growth | NA | 2.50% | NA% | NA% | NA% |
Current Ratio | 28.63 | 4.63 | 30.20 | 5.16 | 7.76 |
Debt/Capital | 12.40% | 0.00% | 10.34% | 0.00% | 0.00% |
Net Margin | NA | -220.28% | NA% | -288.72% | -410.47% |
Return on Equity | -52.43% | -61.83% | -22.88% | -61.83% | -12.61% |
Sales/Assets | NA | 0.22 | NA | 0.18 | 0.02 |
Proj. Sales Growth (F1/F0) | NA | 1.36% | NA% | 3.76% | 13.03% |
Momentum Score | VERA: A | Industry [X] | ABOS: C | AADI: D | ABCL: D |
---|---|---|---|---|---|
Zacks Rank | 4 | 3 | 4 | 2 | |
VGM Score | D | D | F | F | |
Daily Price Chg | -2.53% | 0.93% | 7.63% | 3.33% | -0.32% |
1 Week Price Chg | 2.78% | 7.48% | 22.08% | 16.54% | 15.98% |
4 Week Price Chg | 1.67% | 0.72% | 6.82% | -8.28% | -3.41% |
12 Week Price Chg | -3.63% | -1.58% | -10.48% | -15.76% | -19.38% |
52 Week Price Chg | 116.18% | -27.04% | -55.10% | -73.00% | -56.43% |
20 Day Average Volume | 604,101 | 214,396 | 658,330 | 312,981 | 2,005,595 |
(F1) EPS Est. Wkly Chg | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
(F1) EPS Est. Mthly Chg | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
(F1) EPS Est. Qtrly Chg | -7.62% | 1.06% | 12.91% | -3.00% | 9.06% |
(Q1) EPS Est. Mthly Chg | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Zacks News for VERA
Wall Street Analysts Believe Vera Therapeutics, Inc. (VERA) Could Rally 86.76%: Here's is How to Trade
VERA: What are Zacks experts saying now?
Zacks Private Portfolio Services